Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) | Synapse
October 1, 2024
Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Figure 2. Outcomes for primary and exploratory arms.